Citadel Advisors
JNCE

Citadel Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Citadel Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,300
Closed -$22.8K – 15717
2023
Q1 		$22.8K Buy
12,300
+4,600
+60% +$5.7K ﹤0.01% 12972
2022
Q4 		$8.55K Buy
+7,700
New +$11K ﹤0.01% 13743
2021
Q4 		– Sell
-13,700
Closed -$102K – 15166
2021
Q3 		$102K Sell
13,700
-7,900
-37% -$48.9K ﹤0.01% 12846
2021
Q2 		$147K Sell
21,600
-5,000
-19% -$41.5K ﹤0.01% 12530
2021
Q1 		$273K Sell
26,600
-30,300
-53% -$332K ﹤0.01% 11056
2020
Q4 		$398K Buy
56,900
+900
+2% +$7K ﹤0.01% 8578
2020
Q3 		$457K Buy
56,000
+43,000
+331% +$267K ﹤0.01% 7460
2020
Q2 		$90K Sell
13,000
-1,500
-10% -$8.09K ﹤0.01% 9055
2020
Q1 		$69K Sell
14,500
-6,700
-32% -$38.6K ﹤0.01% 8864
2019
Q4 		$185K Buy
+21,200
New +$115K ﹤0.01% 8249
2019
Q3 		– Sell
-10,400
Closed -$51K – 9934
2019
Q2 		$51K Buy
+10,400
New +$55.2K ﹤0.01% 8726

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Citadel Advisors's JNCE Position: Q2 2023 in Review

Citadel Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 77,599 shares — an estimated $144K sold.

Citadel Advisors first reported a position in JNCE in Q2 2017 and held it in 22 quarters. The position peaked at $20.1M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Citadel Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 77,599 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $144K.
  • Citadel Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 22 quarters.
  • Citadel Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $20.1M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.